

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/05943

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO
Inventive Step (IS)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO
Industrial Applicability (IA)	Claims	(Please See supplemental sheet)	YES
	Claims	(Please See supplemental sheet)	NO

**2. citations and explanations (Rule 70.7)**

Claim 1 lacks novelty under PCT Article 33(2) as being anticipated by WO 98/36639 (Ultradent Products).

The reference discloses that the compound bis-glycerol methacrylate phosphate is useable as a polymerizable adhesion monomer in dental compositions.

Claim 1 lacks novelty under PCT Article 33(2) as being anticipated by JP 5-311200 (Nagayama).

The reference purportedly describes bis(3-(2-ethylpentyl)oxy-2-hydroxy-1-propyl)phosphate as a detergent additive.

Claim 1 lacks novelty under PCT Article 33(2) as being anticipated by JP 57-167364 (Sankin Industry).

The reference teaches that bis(3-methacryloyloxy-2-chloro-1-propyl)phosphate is useful in dental and bone cements as an polymerizable adhesion monomer.

Claim 1 lacks novelty under PCT Article 33(2) as being anticipated by JP 49-002266 (Hosoda).

The reference teaches that bis(3-(2-propenyl)oxy-2-hydroxy-1-propyl)(phosphate) is useful in compositions applied to steel as a blackening agent.

Claim 5 lacks novelty under PCT Article 33(2) as being anticipated by JP 58-10559 (Okumura).

The reference discloses methyl 2-chloro-3-sulfothiopropionate as an intermediate in the synthesis of cysteine.

Claim 1 lacks novelty under PCT Article 33(2) as being anticipated by JP 63-265972 (Tagashira et al.).

The reference teaches that ammonium bis-glycerol methacrylate phosphate is useable in adhesive formulations.

Claims 1 and 2 lack novelty under PCT Article 33(2) as being anticipated by U.S. Patent No. 4,504,409 (Tsutsumi et al.).

The reference describes a class of compounds that includes bis(3-hydrocarbyloxy-2-hydroxy-1-propyl)phosphate and specifically bis(3-dodecyloxy-2-hydroxy-1-propyl)phosphate and bis(3-(Continued on Supplemental Sheet.)

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): A61K 31/255, 31/66; C07F 9/09; C07C 305/10, 305/06 and US Cl.: 514/120, 125, 129, 517; 558/32, 34, 179, 182, 183, 186, 188

**I. BASIS OF REPORT:**

5. (Some) amendments are considered to go beyond the disclosure as filed:

NONE

**V. 1. REASONED STATEMENTS:**

The report as to Novelty was positive (YES) with respect to claims 3, 4 and 6-57.

The report as to Novelty was negative (NO) with respect to claims 1, 2 and 5.

The report as to Inventive Step was positive (YES) with respect to claims 4,6,7,10,11,16,17,19,23-27,33 and 35-57.

The report as to Inventive Step was negative (NO) with respect to claims 1,2,3,5,8,9,12-15,18,20-22,28-32 and 34.

The report as to Industrial Applicability was positive (YES) with respect to claims 1-57.

The report as to Industrial Applicability was negative (NO) with respect to claims NONE.

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):****octadecyloxy-2-hydroxy-1-propyl)phosphate**; note column 3, formulae (d) and (e).

Claims 1,2,3,5,8,9,12-15,18,20-22,28-32 and 34 lack an inventive step under PCT Article 33(3) as being obvious over U.S. Patent No. 4,504,409 (Tsutsumi et al.).

This invention relates to a broad class of organophosphate diesters that includes bis(3-hydrocarbyloxy-2-hydroxy-1-propyl)phosphates. The compounds are alleged to be useful to treat apoptosis and dermatological conditions such as wrinkling and hair loss. The reference describes this class of compounds and teaches that they can be used as emulsifying agents exhibiting low irritation to skin. This invention lacks inventive step because the person having ordinary skill in the art would have been motivated to prepare them for use in personal care products where their property of manifesting reduced irritation would make them desirable, for example, for use in cosmetics. In column 4, line 48, through column 5, line 16, other compounding ingredients are described that are consistent with use in cosmetics. These include surfactants, fats, vitamins, and antimicrobials.

Claims 4,6,7,10,11,16,17,19,23-27,33 and 35-57 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest compositions of the compounds of claim 1 with PEG or proteins, or methods of use wherein the compounds are administered to treat apoptosis or apoptosis-related disorders.

Claims 1-57 meet the criteria set out in PCT Article 33(4) because the compounds have industrial applicability as pharmacological agents for the treatment of apoptosis or apoptosis-related disorders.

NEW CITATIONS

none

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> A61K 31/255, 31/66, C07F 9/09, C07C 305/10, 305/06		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/47101</b>
			<b>(43) International Publication Date:</b> 23 September 1999 (23.09.99)
<b>(21) International Application Number:</b> PCT/US99/05943		<b>(74) Agents:</b> BROWN, Theresa, A. et al.; Sheridan Ross P.C., Suite 3500, 1700 Lincoln Street, Denver, CO 80203-4501 (US).	
<b>(22) International Filing Date:</b> 17 March 1999 (17.03.99)		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<b>(30) Priority Data:</b> 60/078,375 18 March 1998 (18.03.98) US		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(71) Applicants (for all designated States except US):</b> LXR BIOTECHNOLOGY, INC. [US/US]; 1401 Marina Way South, Richmond, CA 94804 (US). OXFORD ASYMMETRY LIMITED [GB/GB]; 151 Milton Park, Abingdon, Oxfordshire OX14 4SD (GB).		<b>(88) Date of publication of the international search report:</b> 25 November 1999 (25.11.99)	
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GODDARD, John, G. [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). PICKER, Donald, H. [US/US]; One Springfield Avenue, Summit, NJ 07901 (US). UMANSKY, Samuil, R. [RU/US]; 6034 Monterey Avenue, Richmond, CA 94805 (US). PRICE, Steven [GB/GB]; 25 Eskdale Road, Stoke-mandeville, Aylesbury, Bucks HP22 5UJ (GB). WIJKMANS, Jacobus, C., H., M. [GB/GB]; 30 Alexander Close, Abingdon, Oxon OX14 1XA (GB). BOYD, Edward, Andrew [GB/GB]; 61 Tamar Way, Didcot, Oxon OX11 7QH (GB). BAXTER, Anthony, David [GB/GB]; 1 Kingfisher Close, Abingdon, Oxon OX14 5NP (GB).			
<b>(54) Title:</b> COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF			
<b>(57) Abstract</b> <p>The invention provides anti-apoptotic compositions containing lysophosphatidic acids and methods for making and using the compositions. Such compositions can also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05943

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/255, 31/66; C07F 9/09; C07C 305/10, 305/06

US CL :514/120, 125, 129, 517; 558/32, 34, 179, 182, 183, 186, 188

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/120, 125, 129, 517; 558/32, 34, 179, 182, 183, 186, 188

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN International®, REGISTRY Database, Accessed 22 June 1999, Structure-based Search Query

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 98/36639 A1 (ULTRADENT PRODUCTS, INC.) 27 August 1998, page 6, first full paragraph.	1
X	JP 05-311200 A2 (NAGAYAMA) 22 November 1993, page 776, formula 2.	1
X	JP 63-265972 A2 (TAGASHIRA et al.) 02 November 1988, page 517, column 1.	1
X	JP 57-167364 A2 (SANKIN INDUSTRY CO.) 15 October 1992, page 513, column 1.	1
X	JP 49-002266 B4 (HOSODA) 19 January 1974, page 108, compound 3.	1
X	JP 58-010559 A2 (AJINOMOTO CO., INC.) 21 January 1983, page 479, column 1, also the table on page 481.	5

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 JUNE 1999

Date of mailing of the international search report

30 SEP 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL G. AMBROSE

Telephone No. (703) 308-1235

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C. 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

10 March 2000 (10.03.00)

International application No.

PCT/US99/05943

Applicant's or agent's file reference

4147-10-PCT

International filing date (day/month/year)

17 March 1999 (17.03.99)

Priority date (day/month/year)

18 March 1998 (18.03.98)

Applicant

GODDARD, John, G. et al \*

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

15 October 1999 (15.10.99)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Sean Taylor

Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Invention Office of the Democratic  
People's  
Republic of Korea  
Kinmaul 1 dong, Bipa Street,  
Moranbong District  
Pyongyang  
RÉPUBLIQUE POPULAIRE DÉMOCRATIQUE  
DE CORÉE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 10 March 2000 (10.03.00)	<b>Applicant's or agent's file reference</b> 4147-10-PCT
<b>International application No.</b> PCT/US99/05943	<b>Priority date (day/month/year)</b> 18 March 1998 (18.03.98)
<b>International filing date (day/month/year)</b> 17 March 1999 (17.03.99)	
<b>Applicant</b> LXR BIOTECHNOLOGY, INC. et al *	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

15 October 1999 (15.10.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  Sean Taylor  Telephone No.: (41-22) 338.83.38
--	--

## PATENT COOPERATION TREATY

## PCT

REC'D 08 AUG 2000

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 4147-10-PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/05943	International filing date (day/month/year) 17 MARCH 1999	Priority date (day/month/year) 18 MARCH 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant LXR BIOTECHNOLOGY, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of <u>4</u> sheets. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of <u>0</u> sheets.
3. This report contains indications relating to the following items: I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 15 OCTOBER 1999	Date of completion of this report 14 JULY 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Michael G. Ambrose</i> MICHAEL G. AMBROSE Telephone No. (703) 308-1235



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/05943

**I. Basis of the report****1. With regard to the elements of the international application:\***☒ the international application as originally filed☒ the description:

pages 1-89 , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the claims:

pages 90-96 , as originally filed  
pages NONE , as amended (together with any statement) under Article 19  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the drawings:

pages 1-15 , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the sequence listing part of the description:

pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☐ contained in the international application in printed form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☒ The amendments have resulted in the cancellation of:**

☒ the description, pages NONE  
☒ the claims, Nos. NONE  
☒ the drawings, sheets/fig NONE

**5. ☒ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05943

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,504,409 A (TSUTSUMI et al.) 12 March 1985, formula I in column 2, also column 3.	1, 2